1620 Investment Advisors, Inc. Gilead Sciences, Inc. Transaction History
1620 Investment Advisors, Inc.
- $125 Million
- Q1 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 6,261 shares of GILD stock, worth $693,906. This represents 0.56% of its overall portfolio holdings.
Number of Shares
6,261
Previous 6,185
1.23%
Holding current value
$693,906
Previous $571,000
22.77%
% of portfolio
0.56%
Previous 0.45%
Shares
12 transactions
Others Institutions Holding GILD
# of Institutions
2,289Shares Held
997MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$13 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.6 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$6.05 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.93 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $139B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...